6Bergman A J, Ebel D, Liu F, et al. Absolute bioavailability of sitagliptin, an oraldipeptidyl peptidase-4 inhibitor, in healthy volunteers[J]. Biopharm Drug Dispos, 2007, 28(6): 315-322.
7Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamics properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo- controlled study in healthy male volunteers[J]. Clin Pharmacol Ther, 2006, 28(1 ): 55-72.
8Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo -controled studies with single oral doses[J]. Clin Pharmacol Ther, 2005, 78(6): 675-688.
9Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose level after an oral glucose tolerance test in patients with type 2 diabetes [J]. J Clin Endocrinol Metab, 2006, 91 (11 ): 4612-4619.
10Migoya EM, Stevens C, Bergman A, et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin[J]. Can J Clin Pharmacol, 2009, 16(1 ): e 165-170.
